Bazedoxifene

Bazedoxifene (TSE-424) is an oral, BBB-penetrant nonsteroidal selective estrogen receptor modulator (SERM), with IC50s of 23 nM and 99 nM for ERα and ERβ, respectively. Bazedoxifene can be used for the research of osteoporosis. Bazedoxifene also acts as an inhibitor of IL-6/GP130 protein-protein interactions and can be used for the research of pancreatic cancer[1][2].

[1]Barry S Komm, et al. Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology. 2005 Sep;146(9):3999-4008.|[2]Xiaojuan Wu, et al. Bazedoxifene as a Novel GP130 Inhibitor for Pancreatic Cancer Therapy. Mol Cancer Ther. 2016 Nov; 15(11): 2609–2619.biorxiv. 2024 May 21.|Breast Cancer Res Treat. 2020 Jan;179(1):67-77.|Eur J Pharmacol. 2023 Mar 24;947:175681.|Free Radic Biol Med. 2023 Aug, 139, 108897.|Glia. 2022 Sep 12.|Gynecol Oncol. 2019 Jul;154(1):199-206.|J Cell Biochem. 2023 Aug 11.|Research Square Preprint. 2020 Nov 4;rs.3.rs-100914.|Research Square Preprint. 2022 Jul.|Cell Rep Methods. 2023 Oct 23;3(10):100599.|J Med Chem. 2020 Oct 8;63(19):11085-11099.|mSphere. 2020 Apr 8;5(2):e00124-20.